Literature DB >> 8035024

Correlation between in vitro and in vivo activity of antifungal agents against Candida species.

E J Anaissie1, N C Karyotakis, R Hachem, M C Dignani, J H Rex, V Paetznick.   

Abstract

The correlation between antifungal susceptibility testing and in vivo response to antifungal therapy was examined in experimental murine candidiasis. In vitro susceptibility testing was done using a microbroth dilution method. Twenty-two Candida albicans, 4 Candida lusitaniae, and 2 Candida krusei isolates were tested against fluconazole, flucytosine, and amphotericin B. In vivo antifungal activity was tested in murine hematogenous candidiasis. Normal CF1 mice were infected with each of the C. albicans strains; immunosuppressed CF1 mice were inoculated with C. lusitaniae or C. krusei. Mice received various doses of antifungal agents, and survival was monitored for 21 days. Kidney fungal burden was examined on day 4. Antifungal therapy significantly prolonged survival and reduced tissue counts in animals infected with organisms susceptible to the agent tested (P < .05). In vitro resistance to a drug predicted its lack of in vivo activity. These results appear to correlate well with outcome of murine hematogenous candidiasis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8035024     DOI: 10.1093/infdis/170.2.384

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  47 in total

1.  Antifungal susceptibility testing of fluconazole by flow cytometry correlates with clinical outcome.

Authors:  C Wenisch; C B Moore; R Krause; E Presterl; P Pichna; D W Denning
Journal:  J Clin Microbiol       Date:  2001-07       Impact factor: 5.948

2.  Correlation between in vitro and in vivo antifungal activities in experimental fluconazole-resistant oropharyngeal and esophageal candidiasis.

Authors:  T J Walsh; C E Gonzalez; S Piscitelli; J D Bacher; J Peter; R Torres; D Shetti; V Katsov; K Kligys; C A Lyman
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

3.  Emerging Issues in Nosocomial Fungal Infections.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-10       Impact factor: 3.725

4.  Collaborative study of antibiotic medium 3 and flow cytometry for identification of amphotericin B-resistant Candida isolates.

Authors:  Vishnu Chaturvedi; Rama Ramani; John H Rex
Journal:  J Clin Microbiol       Date:  2004-05       Impact factor: 5.948

Review 5.  Susceptibility testing of fungi: current status of correlation of in vitro data with clinical outcome.

Authors:  M A Ghannoum; J H Rex; J N Galgiani
Journal:  J Clin Microbiol       Date:  1996-03       Impact factor: 5.948

6.  Clinical correlates of antifungal macrodilution susceptibility test results for non-AIDS patients with severe Candida infections treated with fluconazole.

Authors:  S C Lee; C P Fung; J S Huang; C J Tsai; K S Chen; H Y Chen; N Lee; L C See; W B Shieh
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

7.  Efficacy of escalating doses of liposomal amphotericin B (AmBisome) against hematogenous Candida lusitaniae and Candida krusei infection in neutropenic mice.

Authors:  N C Karyotakis; E J Anaissie
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

8.  Effect of prolonged fluconazole treatment on Candida albicans in diffusion chambers implanted into mice.

Authors:  Peter G Sohnle; Beth L Hahn
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

Review 9.  Fluconazole. An update of its antimicrobial activity, pharmacokinetic properties, and therapeutic use in vaginal candidiasis.

Authors:  C M Perry; R Whittington; D McTavish
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

10.  Fluconazole versus Candida albicans: a complex relationship.

Authors:  J R Graybill; E Montalbo; W R Kirkpatrick; M F Luther; S G Revankar; T F Patterson
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.